Criterium, Inc.
Clinical trials sponsored by Criterium, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cocktail of three drugs targets Hard-to-Treat breast cancer Results expected Jun 2027 (estimated)
-
New cocktail of three drugs targets Hard-to-Treat breast cancer
Disease control OngoingThis Phase 2 trial is testing whether a combination of three drugs—tucatinib, eribulin, and trastuzumab—is safe and effective for people with advanced HER2+ breast cancer that has not responded to prior treatments. The study will enroll 30 participants and measure tumor shrinkage…
Phase 2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Blood test could spot hidden breast cancer early and guide Life-Saving treatment
Disease control OngoingThis study is for people with a high-risk type of breast cancer (ER+/HER2-) who have finished initial treatment but still face a chance of the cancer coming back. Researchers will use a simple blood test to look for tiny bits of tumor DNA. If found, participants will be randomly …
Phase 2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug cocktail targets aggressive breast cancer
Disease control OngoingThis study tests a combination of two targeted drugs, tucatinib and alpelisib, in people with a specific genetic mutation (PIK3CA) and HER2-positive advanced breast cancer. About 40 adults whose cancer has spread or cannot be removed will take these pills daily. The goal is to se…
Phase 1/2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC